dabigatran etexilát+pharma 75mg tvrdá tobolka
+pharma arzneimittel gmbh, graz array - 17915 dabigatran-etexilÁt-mesilÁt - tvrdá tobolka - 75mg - dabigatran-etexilÁt
tracrium 10mg/ml injekční/infuzní roztok
aspen pharma trading limited, dublin array - 4595 atrakurium-besilÁt - injekční/infuzní roztok - 10mg/ml - atrakurium
tracrium 10mg/ml injekční/infuzní roztok
aspen pharma trading limited, dublin array - 4595 atrakurium-besilÁt - injekční/infuzní roztok - 10mg/ml - atrakurium
tracrium 10mg/ml injekční/infuzní roztok
aspen pharma trading limited, dublin array - 4595 atrakurium-besilÁt - injekční/infuzní roztok - 10mg/ml - atrakurium
amlodipine medreg 10mg tableta
medreg s.r.o., praha array - 12990 amlodipin-besilÁt - tableta - 10mg - amlodipin
amlodipine medreg 5mg tableta
medreg s.r.o., praha array - 12990 amlodipin-besilÁt - tableta - 5mg - amlodipin
amlodipine / valsartan mylan
mylan pharmaceuticals limited - amlodipine besilate, valsartan - hypertenze - agens působící na systém renin-angiotenzin - léčba esenciální hypertenze. amlodipin/valsartan mylan je indikován u dospělých, jejichž krevní tlak není dostatečně kontrolován monoterapií buď amlodipinem nebo valsartanem.
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidla - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st elevace akutního infarktu myokardu, v kombinaci s asa u medikamentózně léčených pacientů vhodných pro trombolytickou terapii. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pro další informace viz bod 5.
copalia
novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertenze - agens působící na systém renin-angiotenzin - léčba esenciální hypertenze. copalia je indikován u pacientů, jejichž krevní tlak není dostatečně kontrolován monoterapií buď amlodipinem nebo valsartanem.
exforge
novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertenze - agens působící na systém renin-angiotenzin - léčba esenciální hypertenze. exforge je indikován u pacientů, jejichž krevní tlak není dostatečně kontrolován monoterapií buď amlodipinem nebo valsartanem.